Pancreatic Cancer Research

ResearcherUniversity of ParmaActive in the last 2 years

Rita Balsano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4368-6973; OpenAlex author ID A5082329452. Sources: OpenAlex.

Their work

Papers
11 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper

Papers 11

  1. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Co-author DOI 10.1093/bjsopen/zrad119↗
  2. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Co-author DOI 10.3390/curroncol30040293↗
  3. "Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer. First author DOI 10.1016/j.critrevonc.2022.103659↗
  4. Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect? First author DOI 10.1177/03008916221132589↗
  5. Should patients on levothyroxine therapy be screened for pancreatic cancer? First author DOI 10.23750/abm.v93i6.13366↗
  6. Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Co-author DOI 10.3390/diagnostics12020286↗
  7. It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer. Co-author DOI 10.3390/life12070960↗
  8. The implication of liquid biopsies to predict chemoresistance in pancreatic cancer. First author DOI 10.20517/cdr.2021.01↗
  9. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Co-author DOI 10.3390/life11080843↗
  10. State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now? Co-author DOI 10.21873/anticanres.13484↗
  11. Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer. First author DOI 10.2174/1381612825666190119125804↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingrid Garajová · 10 shared papers, 2018–2024 · strength 1.58
  2. Francesco Leonardi · 5 shared papers, 2021–2024 · strength 0.82
  3. Elisa Giovannetti · 5 shared papers, 2018–2024 · strength 0.74
  4. Annalisa Comandatore · 3 shared papers, 2022–2024 · strength 0.48
  5. Luca Morelli · 3 shared papers, 2022–2024 · strength 0.48
  6. Graziana Digiacomo · 2 shared papers, 2021–2022 · strength 0.32
  7. Andrea Cavazzoni · 2 shared papers, 2021–2022 · strength 0.32
  8. Benoît Immordino · 2 shared papers, 2022 · strength 0.32
  9. Mjriam Capula · 2 shared papers, 2022 · strength 0.32
  10. Silvia Bozzarelli · 1 shared paper, 2023 · strength 0.24
  11. Andrea Spallanzani · 1 shared paper, 2024 · strength 0.16
  12. Lenka N.C. Boyd · 1 shared paper, 2024 · strength 0.16
  13. Gregorio Di Franco · 1 shared paper, 2024 · strength 0.16
  14. Manuel Gentiluomo · 1 shared paper, 2024 · strength 0.16
  15. Geert Kazemier M · 1 shared paper, 2024 · strength 0.16
  16. Umberto Malapelle · 1 shared paper, 2022 · strength 0.15
  17. Elisabetta Pietri · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.